Match!

Rediscovering the sweet spot in drug discovery

Published on Dec 1, 2003in Drug Discovery Today6.88
· DOI :10.1016/S1359-6446(03)02902-7
David Brown5
Estimated H-index: 5
(University of Hertfordshire),
Giulio Superti-Furga76
Estimated H-index: 76
Abstract
Advances over the past decade in drug discovery technologies have not yet led to an increase in productivity. We analyzed the reasons that have led to this juncture and identify the selection of the right target and the right lead as crucial. New approaches are required to take full advantage of the genomics revolution. For targets, methods are becoming available for high-throughput proteome analysis and pathway characterization that synergize with studies of disease association and differential expression. For leads, methods are being developed that ‘reverse’ the high-throughput screening paradigm by mapping drugs and drug-like compounds back onto the proteome. The synergy between pathway mapping and compound mapping could allow the pharmaceutical and biotechnology industries to rediscover the sweet spot of research productivity.
  • References (44)
  • Citations (145)
📖 Papers frequently viewed together
2,166 Citations
389 Citations
362 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References44
Newest
The mitochondrial respiratory chain has the crucial function of supplying the cell with energy in the form of ATP. Mutations affecting this chain can arise in mitochondrial or nuclear DNA and cause diseases known as mitochondrial encephalomyopathies. Because the rules of inheritance of mitochondrial and nuclear DNA differ considerably, these brain–muscle syndromes often have unpredictable clinical and genetic features.
1,151 CitationsSource
In an attempt to better understand and control the processes that regulate stem cell fate, we have set out to identify small molecules that induce neuronal differentiation in embryonic stem cells (ESCs). A high-throughput phenotypic cell-based screen of kinase-directed combinatorial libraries led to the discovery of TWS119, a 4,6-disubstituted pyrrolopyrimidine that can induce neurogenesis in murine ESCs. The target of TWS119 was shown to be glycogen synthase kinase-3β (GSK-3β) by both affinity-...
305 CitationsSource
#1Donmienne Leung (Scripps Research Institute)H-Index: 9
#2Christophe Hardouin (Scripps Research Institute)H-Index: 13
Last. Benjamin F. Cravatt (Scripps Research Institute)H-Index: 113
view all 4 authors...
To realize the promise of genomics-based therapeutics, new methods are needed to accelerate the discovery of small molecules that selectively modulate protein activity. Toward this end, advances in combinatorial synthesis have provided unprecedented access to large compound libraries of considerable structural complexity and diversity1,2, shifting the bottleneck in drug discovery to the development of efficient screens for protein targets3. Screening for reversible enzyme inhibitors typically re...
263 CitationsSource
Over the past couple of years, there has been a surge in the rate of discovery of proteins that interact with the products of the breast-cancer–susceptibility genes BRCA1 and BRCA2. Several finding...
59 CitationsSource
#1Yoshiya OdaH-Index: 37
#2Takashi OwaH-Index: 19
Last. Takeshi NagasuH-Index: 28
view all 10 authors...
We have developed a systematic strategy for drug target identification. This consists of the following sequential steps: (1) enrichment of total binding proteins using two differential affinity matrixes upon which are immobilized positive and negative chemical structures for drug activity, respectively; (2) covalent labeling of the proteins with a new cleavable isotope-coded affinity tag (ICAT) reagent, followed by proteolysis of the combined proteins; (3) isolation, identification, and relative...
160 CitationsSource
#1Konrad BleicherH-Index: 15
#2Hans-Joachim BöhmH-Index: 26
Last. Alexander AlanineH-Index: 17
view all 4 authors...
542 CitationsSource
#1Konrad Bleicher (Hoffmann-La Roche)H-Index: 15
#2Hans-Joachim Böhm (Hoffmann-La Roche)H-Index: 26
Last. Alexander Alanine (Hoffmann-La Roche)H-Index: 17
view all 4 authors...
The identification of small-molecule modulators of protein function, and the process of transforming these into high-content lead series, are key activities in modern drug discovery. The decisions taken during this process have far-reaching consequences for success later in lead optimization and even more crucially in clinical development. Recently, there has been an increased focus on these activities due to escalating downstream costs resulting from high clinical failure rates. In addition, th...
707 CitationsSource
Abstract The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug–protein interactions and protein–protein interactions. The first tier of the biotechnology industry has now become the most prod...
136 CitationsSource
#1Tony Pawson (Mount Sinai Hospital)H-Index: 139
#2Piers Nash (Mount Sinai Hospital)H-Index: 31
The sequencing of complete genomes provides a list that includes the proteins responsible for cellular regulation. However, this does not immediately reveal what these proteins do, nor how they are assembled into the molecular machines and functional networks that control cellular behavior. The regulation of many different cellular processes requires the use of protein interaction domains to direct the association of polypeptides with one another and with phospholipids, small molecules, or nucle...
1,201 CitationsSource
#1Eric E. SchadtH-Index: 98
#2Stephanie A. Monks (UW: University of Washington)H-Index: 15
Last. Stephen H. Friend (MSD: Merck & Co.)H-Index: 61
view all 3 authors...
Application of statistical genetics approaches to variations in mRNA transcript abundances in segregating populations can be used to identify genes and pathways associated with common human diseases. The combination of this genetic information with gene expression and clinical trait data can also be used to identify subtypes of a disease and the genetic loci specific to each subtype. Here we highlight results from some of our recent work in this area and further explore the many possibilities th...
65 CitationsSource
Cited By145
Newest
#1Md. Sahab Uddin (SEU: Southeast University)H-Index: 9
#2Md. Tanvir Kabir (BRACU: BRAC University)H-Index: 4
Last. Mohamed M. Abdel-Daim (KSU: King Saud University)H-Index: 24
view all 9 authors...
Alzheimer’s disease (AD) is the most common cause of dementia among older people, and the prevalence of this disease is estimated to rise quickly in the upcoming years. Unfortunately, almost all of the drug candidates tested for AD until now have failed to exhibit any efficacy. Henceforth, there is an increased necessity to avert and/or slow down the advancement of AD. It is known that one of the major pathological characteristics of AD is the presence of senile plaques (SPs) in the brain. These...
4 CitationsSource
#1Minoru Ishikawa (Tohoku University)H-Index: 24
#2Shusuke Tomoshige (Tohoku University)H-Index: 4
Last. Mikihiko NaitoH-Index: 44
view all 4 authors...
New therapeutic modalities are needed to address the problem of pathological but undruggable proteins. One possible approach is the induction of protein degradation by chimeric drugs composed of a ubiquitin ligase (E3) ligand coupled to a ligand for the target protein. This article reviews chimeric drugs that decrease the level of specific proteins such as proteolysis targeting chimeric molecules (PROTACs) and specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers...
Source
#1Yaxia Yuan (PKU: Peking University)H-Index: 10
Last. Luhua LaiH-Index: 42
view all 3 authors...
With the rapid development of systems-based pharmacology and poly-pharmacology, method development for rational design of multi-target drugs has becoming urgent. In this paper, we present the first de novo multi-target drug design program LigBuilder V3, which can be used to design ligands to target multiple receptors, multiple binding sites of one receptor, or various conformations of one receptor. LigBuilder V3 is generally applicable in de novo multi-target drug design and optimization, especi...
2 CitationsSource
#1Marc RuoßH-Index: 2
#2Massoud Vosough (Royan Institute)H-Index: 9
Last. Jan G. Hengstler (Technical University of Dortmund)H-Index: 52
view all 11 authors...
Abstract Hepatotoxicity is among the most frequent reasons for drug withdrawal from the market. Therefore, there is an urgent need for reliable predictive in vitro tests, which unfailingly identify hepatotoxic drug candidates, reduce drug development time, expenses and the number of test animals. Currently, human hepatocytes represent the gold standard. However, the use of hepatocytes is challenging since the cells are not constantly available and lose their metabolic activity in culture. To sol...
1 CitationsSource
#2Chang LiuH-Index: 1
Last. Ivet BaharH-Index: 63
view all 5 authors...
Source
#1Hanxun Wang (SPU: Shenyang Pharmaceutical University)H-Index: 1
#2Yinli Gao (SPU: Shenyang Pharmaceutical University)
Last. Maosheng Cheng (SPU: Shenyang Pharmaceutical University)H-Index: 16
view all 4 authors...
BACKGROUND: Poor selectivity of drug candidates may lead to toxicity and side effects accounting for as high as 60% failure rate, thus selectivity is consistently significant and challenging for drug discovery. OBJECTIVE: To find highly specific small molecules towards very similar protein targets, multiple strategies are always employed, including (1) To make use of the diverse shape of binding pocket to avoid steric bump; (2) To increase binding affinities for favorite residues; (3) To achieve...
Source
#2Alejandro Cabrera-Andrade (UDLAP: Universidad de las Américas Puebla)H-Index: 4
Last. Cristian R. MunteanuH-Index: 20
view all 10 authors...
Background: Druggable proteins are a trending topic in drug design. The druggable proteome can be defined as the percentage of proteins that have the capacity to bind an antibody or small molecule with adequate chemical properties and affinity. The screening and in silico modeling are critical activities for the reduction of experimental costs. Methods: The current work proposes a unique prediction model for druggable proteins using amino acid composition descriptors of protein sequences and 13 ...
3 CitationsSource
#1Agostino BrunoH-Index: 13
#2Gabriele CostantinoH-Index: 32
Last. Marco RadiH-Index: 23
view all 4 authors...
BACKGROUND: Discovery and development of a new drug is a long lasting and expensive journey that takes around 20 years from starting idea to approval and marketing of new medication. Despite RD (ii) hit identification; (iii) hit-to-lead; and (iv) lead optimization. Each of these steps has been described in details, providing a useful overview on the role played by in silico tools in the decision-making process to speed-up the discovery of new drugs.
5 CitationsSource
#1Harbinder Singh (G.N.D.U.: Guru Nanak Dev University)H-Index: 6
#2Nihar Kinarivala (Kettering University)H-Index: 5
Last. Sahil Sharma (G.N.D.U.: Guru Nanak Dev University)H-Index: 16
view all 3 authors...
: We live in a world with complex diseases such as cancer which cannot be cured with one-compound one-target based therapeutic paradigm. This could be due to the involvement of multiple pathogenic mechanisms. One-compound-various-targets stratagem has become a prevailing research topic in anti-cancer drug discovery. The simultaneous interruption of two or more targets has improved the therapeutic efficacy as compared to the specific targeted based therapy. In this review, six types of dual targe...
1 CitationsSource
The discovery of new pharmaceutical drugs is one of the preeminent tasks---scientifically, economically, and socially---in biomedical research. Advances in informatics and computational biology have increased productivity at many stages of the drug discovery pipeline. Nevertheless, drug discovery has slowed, largely due to the reliance on small molecules as the primary source of novel hypotheses. In recent years, it has become apparent that natural products (such as plant metabolites, animal tox...
2 CitationsSource